ARDELYX INC (ARDX) Stock Price, Quote, News and Overview
NASDAQ:ARDX - Nasdaq - US0396971071 - Common Stock - Currency: USD
ARDX Quote, Performance and Key Statistics
NASDAQ:ARDX (5/13/2025, 12:52:08 PM)
3.35
-0.18 (-5.1%)
The current stock price of ARDX is 3.35 USD. In the past month the price decreased by -20.85%. In the past year, price decreased by -54.8%.
ARDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.33 | 333.06B | ||
| AMGN | AMGEN INC | 13.03 | 145.38B | ||
| GILD | GILEAD SCIENCES INC | 13.18 | 127.01B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.79B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.85 | 61.49B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.58B | ||
| ARGX | ARGENX SE - ADR | 92.28 | 33.08B | ||
| ONC | BEIGENE LTD-ADR | 5.57 | 24.17B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.14B | ||
| NTRA | NATERA INC | N/A | 20.87B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.28B | ||
| BIIB | BIOGEN INC | 7.77 | 18.02B |
Related stock screener links
About ARDX
Company Profile
Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The company is headquartered in Waltham, Massachusetts and currently employs 395 full-time employees. The company went IPO on 2014-06-19. The firm has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor). IBSRELA is a first-in-class NHE3 inhibitor approved by the United States FDA for the treatment of irritable bowel syndrome with constipation in adults. XPHOZAH is a first-in-class phosphate absorption inhibitor approved in the United States to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. The company has agreements for the development and commercialization of tenapanor outside of the United States. Kyowa Kirin commercializes PHOZEVEL (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma.
Company Info
ARDELYX INC
400 Fifth Ave, Suite 210
Waltham MASSACHUSETTS 94555 US
CEO: Michael Raab
Employees: 395
Phone: 15107457047
ARDELYX INC / ARDX FAQ
What is the stock price of ARDELYX INC today?
The current stock price of ARDX is 3.35 USD. The price decreased by -5.1% in the last trading session.
What is the ticker symbol for ARDELYX INC stock?
The exchange symbol of ARDELYX INC is ARDX and it is listed on the Nasdaq exchange.
On which exchange is ARDX stock listed?
ARDX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ARDELYX INC stock?
18 analysts have analysed ARDX and the average price target is 10.52 USD. This implies a price increase of 214.17% is expected in the next year compared to the current price of 3.35. Check the ARDELYX INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ARDELYX INC worth?
ARDELYX INC (ARDX) has a market capitalization of 798.51M USD. This makes ARDX a Small Cap stock.
How many employees does ARDELYX INC have?
ARDELYX INC (ARDX) currently has 395 employees.
What are the support and resistance levels for ARDELYX INC (ARDX) stock?
ARDELYX INC (ARDX) has a resistance level at 5.05. Check the full technical report for a detailed analysis of ARDX support and resistance levels.
Is ARDELYX INC (ARDX) expected to grow?
The Revenue of ARDELYX INC (ARDX) is expected to grow by 12.44% in the next year. Check the estimates tab for more information on the ARDX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ARDELYX INC (ARDX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ARDX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ARDX, evaluating the profitability, health, valuation and growth aspects
- ARDELYX INC (ARDX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ARDELYX INC (ARDX) Sales and EPS estimates to see what analysts future expectations are.
- ARDELYX INC (ARDX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ARDELYX INC (ARDX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ARDELYX INC (ARDX) Stock Chart to make your own analysis
- ARDELYX INC (ARDX) Latest news and press-releases to stay up to date.
Does ARDELYX INC (ARDX) stock pay dividends?
ARDX does not pay a dividend.
When does ARDELYX INC (ARDX) report earnings?
ARDELYX INC (ARDX) will report earnings on 2025-07-30, before the market open.
What is the Price/Earnings (PE) ratio of ARDELYX INC (ARDX)?
ARDELYX INC (ARDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.22).
What is the Short Interest ratio of ARDELYX INC (ARDX) stock?
The outstanding short interest for ARDELYX INC (ARDX) is 12.83% of its float. Check the ownership tab for more information on the ARDX short interest.
ARDX Technical Analysis
ARDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ARDX. ARDX may be in some trouble as it scores bad on both profitability and health.
ARDX Financial Highlights
Over the last trailing twelve months ARDX reported a non-GAAP Earnings per Share(EPS) of -0.22. The EPS increased by 20.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.11% | ||
| ROE | -36.91% | ||
| Debt/Equity | 1.04 |
ARDX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to ARDX. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of -51.3% and a revenue growth 12.44% for ARDX